## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.7% below STRENGTH zone (3.0-6.0%); PEG 1.22 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($461.95)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. HCA Healthcare to give $4.8m to support Pepperdine University’s nursing school**
- Source: Yahoo | 20251208T101200 | Bullish | Relevance: 99%
-  HCA Healthcare has committed $4.8 million to Pepperdine University’s School of Nursing to help address the national nursing shortage. This investment will support the development of a new 30,000-square-foot facility on the Calabasas campus, featuring advanced simulation laboratories. Students will also have opportunities for clinical rotations at HCA Healthcare’s Los Robles Regional Medical Center.

**2. Invesco Ltd. Sells 113,115 Shares of HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251206T112555 | Somewhat-Bullish | Relevance: 98%
- Invesco Ltd. reduced its stake in HCA Healthcare, Inc. by 9.4% in the second quarter, selling 113,115 shares and now owning 1,089,100 shares valued at $417,234,000. Other institutional investors also adjusted their positions in HCA, while analysts have given the stock a "Moderate Buy" consensus rating with an average target price of $474.53. Insider selling occurred recently, with EVP Michael R. Mcalevey and EVP Michael S. Cuffe selling shares.

**3. HCA Healthcare (NYSE: HCA) appoints Virginia Tenpenny to lead community engagement**
- Source: Stock Titan | 20251209T133231 | Bullish | Relevance: 98%
- HCA Healthcare has appointed Virginia Tenpenny as its new Vice President of Community Engagement, effective January 12, 2026. Tenpenny, who has over two decades of experience in corporate community impact, will lead the company's community engagement strategy, succeeding the retiring Joanne Pulles. This role oversees social and charitable investments, colleague giving, community outreach, and strategic partnerships.

**4. CW Advisors LLC Has $3.31 Million Position in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251207T092016 | Bullish | Relevance: 98%
-  CW Advisors LLC significantly increased its stake in HCA Healthcare by 576.9% in Q2, bringing its total holdings to 8,644 shares valued at approximately $3.31 million. HCA Healthcare exceeded Q3 expectations with EPS of $6.96 and $19.16 billion in revenue, setting positive FY2025 guidance. Analysts maintain a "Moderate Buy" rating with a consensus price target of $474.53 for the company.

**5. California Public Employees Retirement System Has $124.64 Million Stock Position in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251208T094854 | Bullish | Relevance: 97%
-  The California Public Employees' Retirement System (CalPERS) recently reduced its HCA Healthcare (NYSE:HCA) holdings by 5.4%, but still maintains a significant position worth approximately $124.64 million. This move comes as other institutional investors, such as Norges Bank and Price T Rowe Associates Inc. MD, have either initiated or significantly boosted their stakes in the company. HCA Healthcare reported strong Q3 earnings, surpassing analyst estimates, and announced a quarterly dividend, indicating healthy financial performance and a commitment to shareholder returns.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | Wells Fargo | $431 | $412 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.0% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $15M sold (4 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.22 suggests fair value with growth premium. Forward P/E 16.3x stretched relative to 8% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $113.5B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.22 |
| Forward P/E | 16.3 |
| Current P/E | 17.6 |
| YoY Growth | 7.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -1.7% to -3.7% (-2.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.7pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.25x) but short-term weakness (below SMA20). MACD histogram bearish (-3.11), momentum weakening. RSI neutral at 53.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.70% (CS: 15) | Weak |
| RSI_14 | 53.4 | Neutral |
| MACD Histogram | -3.11 | Bearish |
| vs SMA20 | 0.997x | Below |
| vs SMA50 | 1.056x | Above |
| vs SMA200 | 1.248x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $485.15
- **Stop Loss:** $461.95 (4.8% risk)
- **Target:** $508.35 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 21
- **Position Value:** $10,188.15
- **Portfolio %:** 10.19%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*